Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.

Sapna Pradyuman PatelGina R PetroniJason RoszikWalter C OlsonNolan A WagesKimberly A Chianese-BullockMark SmolkinNikole VarhegyiElizabeth GaughanKelly T SmithKathleen HadenEmily H HallSacha GnjaticPatrick HwuCraig L Slingluff

Published in: Journal for immunotherapy of cancer (2022)

NCT02126579.

Keyphrases

toll like receptor
inflammatory response
nuclear factor
phase iii
early stage
study protocol
immune response
phase ii
lymph node
clinical trial
skin cancer
prognostic factors
randomized controlled trial
double blind